A new cancer treatment has shown potential in improving survival rates for certain patients. This experimental vaccine uses a tailored approach to target melanoma. Details of the trial's success were shared by two major companies.

Further information is available from the companies that announced the results. The trial involved patients at high risk and was a large, late-stage study.

The companies' announcement was made on a Wednesday, revealing the vaccine's success in extending life span.